Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 6/20 | 0.62 |
| ▸ | SRC | P12931 | 5/20 | 0.62 |
| ▸ | TEK | Q02763 | 5/20 | 0.62 |
| ▸ | BTK | Q06187 | 7/20 | 0.54 |
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | HCK | P08631 | 7/20 | 0.49 |
| ▸ | FLT3 | P36888 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6457819 | 0.95 | LCK (0.61) | LCKSRCTEKBTKKDR | |
| SCHEMBL6465342 | 0.92 | LCK (0.67) | LCKSRCTEKBTKKDR | |
| SCHEMBL6462024 | 0.92 | LCK (0.60) | LCKSRCTEKBTKKDR | |
| SCHEMBL6462888 | 0.90 | SRC (0.70) | LCKSRCTEKBTKKDR | |
| SCHEMBL6459567 | 0.88 | LCK (0.59) | LCKSRCTEKBTKKDR | |
| SCHEMBL6465478 | 0.87 | LCK (0.63) | LCKSRCTEKBTKKDR | |
| SCHEMBL6466133 | 0.87 | LCK (0.62) | LCKSRCTEKBTKKDR | |
| SCHEMBL7851979 | 0.86 | LCK (0.65) | LCKSRCTEKBTKKDR | |
| SCHEMBL6459028 | 0.86 | LCK (0.62) | LCKSRCTEKBTKKDR | |
| SCHEMBL6458223 | 0.86 | LCK (0.64) | LCKSRCTEKBTKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | LCK 1/4885SRC 46/4885TEK 1465/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | LCK 6/4885SRC 206/4885TEK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.